Astex urged to hold out for more from Otuska; AstraZeneca sells landmark building; Sanofi close to Elder deal;

@FiercePharma: Glaxo said to be near $1.6B Lucozade-Ribena sale to Japan's Suntory. Latest in series of brand sales. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: Bristol-Myers Squibb flees high cost of East Coast with new center in Tampa, FL. Moving some jobs from NJ. Report | Follow @EricPFierce

@CarlyHFierce: Departure of new Vivus CEO Zook tops the list of this week's hirings, firings & other movements in pharma/biotech. Chutes & Ladders | Follow @CarlyHFierce

> Analysts suggest Astex Pharmaceuticals ($ASTX) should hold out for a much better deal than the $886 million Abilify-maker Otuska offered this week. Story

> Amgen ($AMGN) has sent a letter to healthcare providers warning that its drugs Neupogen and Neulasta have been associated with potentially fatal capillary leak syndrome (CLS). Report

> Biotech investor David Blech says if he had left well enough alone, he would be a billionaire, not a prisoner. Story

> AstraZeneca ($AZN) has sold the landmark Rollins Building in Fairfax, DE, to investors for a reported $10.5 million. Report

> Novartis ($NVS) said today that it has an exclusive global licensing and research collaboration agreement with Louisville, KY-based Regenerex to use its Facilitating Cell Therapy (FCRx) platform in kidney transplantation. Release | More from FierceBiotech

Medical Device News

@FierceMedDev: Enzymatics jumps into next-gen Dx space with $50M startup buy. More | Follow @FierceMedDev

@MarkHFierce: Better sanitation is linked to more Alzheimer's cases. Article | Follow @MarkHFierce

@MichaelGFierce: Myriad rolls out next-gen Dx for 8 major cancers. Story | Follow @MichaelGFierce

> Rented Medtronic tools linked to possible disease exposure. News

> Enzymatics jumps into next-gen Dx space with $50M startup buy. Report

> Report: KKR favored bidder in Panasonic's billion-dollar health unit sale. Story

> India advances effort to modernize medical device regs. Item

Biotech News

@FierceBiotech: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Article from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: Crowdfunding cash for biotech startup Perle (diabetes). Press release | Follow @JohnCFierce

@Ry_McBride: UPDATED: No end of biotech IPO frenzy in sight. Special report | Follow @Ry_McBride

@EmilyMFierce: Making iPS cells safer for use in humans through the study of a cellular odd fellow. More from Stanford | Follow @EmilyMFierce

> Novartis strikes stem cell deal to aid transplant patients. Story

> NYT: Blech says he could have been a biotech billionaire. Article

> Under FDA priority review, Mallinckrodt's pain med succeeds in PhIII. More

And Finally... Reports say that Sanofi ($SNY) is closing in on a deal to buy India's Elder Pharma. Story

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.